395 related articles for article (PubMed ID: 8898960)
1. Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.
Sartoris S; Tosi G; De Lerma Barbaro A; Cestari T; Accolla RS
Eur J Immunol; 1996 Oct; 26(10):2456-60. PubMed ID: 8898960
[TBL] [Abstract][Full Text] [Related]
2. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.
Sartoris S; Valle MT; Barbaro AL; Tosi G; Cestari T; D'Agostino A; Megiovanni AM; Manca F; Accolla RS
J Immunol; 1998 Jul; 161(2):814-20. PubMed ID: 9670958
[TBL] [Abstract][Full Text] [Related]
3. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant.
Zhou H; Su HS; Zhang X; Douhan J; Glimcher LH
J Immunol; 1997 May; 158(10):4741-9. PubMed ID: 9144488
[TBL] [Abstract][Full Text] [Related]
4. BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells.
Piskurich JF; Lin KI; Lin Y; Wang Y; Ting JP; Calame K
Nat Immunol; 2000 Dec; 1(6):526-32. PubMed ID: 11101876
[TBL] [Abstract][Full Text] [Related]
5. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).
Cycon KA; Rimsza LM; Murphy SP
Exp Hematol; 2009 Feb; 37(2):184-194. PubMed ID: 19081173
[TBL] [Abstract][Full Text] [Related]
6. Distinct mechanisms regulate MHC class II gene expression in B cells and macrophages.
Maffei A; Scarpellino L; Bernard M; Carra G; Jotterand-Bellomo M; Guardiola J; Accolla RS
J Immunol; 1987 Aug; 139(3):942-8. PubMed ID: 3110290
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional control of MHC class II gene expression during differentiation from B cells to plasma cells.
Dellabona P; Latron F; Maffei A; Scarpellino L; Accolla RS
J Immunol; 1989 Apr; 142(8):2902-10. PubMed ID: 2495328
[TBL] [Abstract][Full Text] [Related]
9. A phenotypically dominant regulatory mechanism suppresses major histocompatibility complex class II gene expression in a murine plasmacytoma.
Venkitaraman AR; Culbert EJ; Feldmann M
Eur J Immunol; 1987 Oct; 17(10):1441-6. PubMed ID: 3500056
[TBL] [Abstract][Full Text] [Related]
10. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).
Steimle V; Otten LA; Zufferey M; Mach B
Cell; 1993 Oct; 75(1):135-46. PubMed ID: 8402893
[TBL] [Abstract][Full Text] [Related]
11. Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells.
Croce M; De Ambrosis A; Corrias MV; Pistoia V; Occhino M; Meazza R; Giron-Michel J; Azzarone B; Accolla RS; Ferrini S
Oncogene; 2003 Oct; 22(49):7848-57. PubMed ID: 14586411
[TBL] [Abstract][Full Text] [Related]
12. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA.
Muhlethaler-Mottet A; Otten LA; Steimle V; Mach B
EMBO J; 1997 May; 16(10):2851-60. PubMed ID: 9184229
[TBL] [Abstract][Full Text] [Related]
13. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
Muczynski KA; Anderson SK; Pious D
J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
[TBL] [Abstract][Full Text] [Related]
14. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.
Souwer Y; Chamuleau ME; van de Loosdrecht AA; Tolosa E; Jorritsma T; Muris JJ; Dinnissen-van Poppel MJ; Snel SN; van de Corput L; Ossenkoppele GJ; Meijer CJ; Neefjes JJ; Marieke van Ham S
Br J Haematol; 2009 May; 145(3):334-43. PubMed ID: 19245431
[TBL] [Abstract][Full Text] [Related]
15. Introduction of exogenous class II trans-activator in MHC class II-deficient ABI fibroblasts results in incomplete rescue of MHC class II antigen expression.
Peijnenburg A; Gobin SJ; van Eggermond MC; Godthelp BC; van Graafeiland N; van den Elsen PJ
J Immunol; 1997 Sep; 159(6):2720-7. PubMed ID: 9300692
[TBL] [Abstract][Full Text] [Related]
16. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
[TBL] [Abstract][Full Text] [Related]
17. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines.
Goodwin BL; Xi H; Tejiram R; Eason DD; Ghosh N; Wright KL; Nagarajan U; Boss JM; Blanck G
Cell Growth Differ; 2001 Jun; 12(6):327-35. PubMed ID: 11432807
[TBL] [Abstract][Full Text] [Related]
18. The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in myelomonocytic cells.
De Lerma Barbaro A; Procopio FA; Mortara L; Tosi G; Accolla RS
Eur J Immunol; 2005 Feb; 35(2):603-11. PubMed ID: 15627980
[TBL] [Abstract][Full Text] [Related]
19. Identification of distinct regions of 5' flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene.
Piskurich JF; Wang Y; Linhoff MW; White LC; Ting JP
J Immunol; 1998 Jan; 160(1):233-40. PubMed ID: 9551976
[TBL] [Abstract][Full Text] [Related]
20. Inducible and constitutive MHC class II gene expression. Distinct tissue-specific genetic controls.
Sartoris S; Scupoli MT; Scarpellino L; Paiola F; Jotterand-Bellomo M; Tridente G; Accolla RS
J Immunol; 1990 Sep; 145(6):1960-7. PubMed ID: 2391425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
